Streptococcal toxic shock syndrome.
Perhaps more noteworthy than the emergence of Streptococcal toxic shock syndrome (StrepTSS) is its persistence for a period of more than 15 years in most geographical areas and an actual increase in incidence in some regions. Early diagnosis remains a problem, and aggressive surgery often cannot be avoided. The continuing rates of mortality and morbidity indicate the need for novel approaches to diagnosis and treatment.
Stevens
D L
DL
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003646:Debridement; D006801:Humans; D012772:Shock, Septic / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D013290:Streptococcal Infections / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D013291:Streptococcus / Q000145:classification / Q000276:immunology / Q000472:pathogenicity / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D014774:Virulence
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha